Immunovia AB (publ) (IMMNOV.ST)
SEK 0.28
(3.38%)
SEK 0.28
(3.38%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.57 Million SEK | 37.55% |
| 2022 | 1.14 Million SEK | 35.66% |
| 2021 | 844 Thousand SEK | 133.15% |
| 2020 | 362 Thousand SEK | 1.69% |
| 2019 | 356 Thousand SEK | 7.04% |
| 2018 | 332.59 Thousand SEK | 123.27% |
| 2017 | 148.96 Thousand SEK | -15.97% |
| 2016 | 177.28 Thousand SEK | -13.6% |
| 2015 | 205.19 Thousand SEK | -42.87% |
| 2014 | 359.16 Thousand SEK | -69.53% |
| 2013 | 1.17 Million SEK | 464.45% |
| 2012 | 208.81 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 156 Thousand SEK | 0.0% |
| 2024 Q2 | 85 Thousand SEK | -45.51% |
| 2023 FY | 1.57 Million SEK | 37.55% |
| 2023 Q2 | 412 Thousand SEK | -20.77% |
| 2023 Q1 | 520 Thousand SEK | 3.59% |
| 2023 Q3 | 488 Thousand SEK | 18.45% |
| 2023 Q4 | 156 Thousand SEK | -68.03% |
| 2022 Q3 | 358 Thousand SEK | 247.57% |
| 2022 FY | 1.14 Million SEK | 35.66% |
| 2022 Q4 | 502 Thousand SEK | 40.22% |
| 2022 Q2 | 103 Thousand SEK | -43.41% |
| 2022 Q1 | 182 Thousand SEK | -40.33% |
| 2021 Q3 | 377 Thousand SEK | 892.11% |
| 2021 Q1 | 123 Thousand SEK | -19.08% |
| 2021 Q2 | 38 Thousand SEK | -69.11% |
| 2021 FY | 844 Thousand SEK | 133.15% |
| 2021 Q4 | 305 Thousand SEK | -19.1% |
| 2020 FY | 362 Thousand SEK | 1.69% |
| 2020 Q1 | 14 Thousand SEK | -68.89% |
| 2020 Q2 | 159 Thousand SEK | 1035.71% |
| 2020 Q4 | 152 Thousand SEK | 310.81% |
| 2020 Q3 | 37 Thousand SEK | -76.73% |
| 2019 Q2 | 154 Thousand SEK | 133.33% |
| 2019 Q4 | 45 Thousand SEK | -51.09% |
| 2019 Q1 | 66 Thousand SEK | -27.94% |
| 2019 FY | 356 Thousand SEK | 7.04% |
| 2019 Q3 | 92 Thousand SEK | -40.26% |
| 2018 FY | 332.59 Thousand SEK | 123.27% |
| 2018 Q4 | 91.59 Thousand SEK | 7.76% |
| 2018 Q3 | 85 Thousand SEK | 93.18% |
| 2018 Q1 | 112 Thousand SEK | 315.38% |
| 2018 Q2 | 44 Thousand SEK | -60.71% |
| 2017 Q1 | 28 Thousand SEK | -73.66% |
| 2017 FY | 148.96 Thousand SEK | -15.97% |
| 2017 Q4 | 26.96 Thousand SEK | -0.14% |
| 2017 Q3 | 27 Thousand SEK | -60.29% |
| 2017 Q2 | 68 Thousand SEK | 142.86% |
| 2016 Q3 | 5000.00 SEK | -92.42% |
| 2016 Q4 | 106.28 Thousand SEK | 2025.68% |
| 2016 FY | 177.28 Thousand SEK | -13.6% |
| 2016 Q2 | 66 Thousand SEK | -98.73% |
| 2016 Q1 | 5.18 Million SEK | 3.43% |
| 2015 FY | 205.19 Thousand SEK | -42.87% |
| 2015 Q4 | 5.01 Million SEK | 0.0% |
| 2015 Q1 | 3.48 Million SEK | 2615.34% |
| 2015 Q3 | 5.01 Million SEK | 44.1% |
| 2015 Q2 | 3.48 Million SEK | 0.0% |
| 2014 Q4 | 128.21 Thousand SEK | 0.0% |
| 2014 Q1 | 51.36 Thousand SEK | 0.0% |
| 2014 Q2 | 51.36 Thousand SEK | 0.0% |
| 2014 Q3 | 128.21 Thousand SEK | 149.61% |
| 2014 FY | 359.16 Thousand SEK | -69.53% |
| 2013 FY | 1.17 Million SEK | 464.45% |
| 2012 FY | 208.81 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AroCell AB (publ) | 43.03 Million SEK | 96.341% |
| Devyser Diagnostics AB (publ) | 169.3 Million SEK | 99.07% |
| Prostatype Genomics AB (publ) | 1.35 Million SEK | -16.15% |
| SenzaGen AB | 49.87 Million SEK | 96.842% |
| Spermosens AB | - SEK | -Infinity% |